Off-the-shelf, on-demand allogeneic CAR-T cells could represent a therapeutic alternative to autologous products for cancer therapy. Here the authors report the preclinical characterization of off-the-shelf CRISPR-Cas9– edited IL-13Rα2-specific allogeneic universal CAR-T cells and the results of a first-in-human phase I trial in patients with high-grade glioma.
- Xuetao Li
- Xiaoyun Shang
- Yulun Huang
